Capricorn Fund Managers Ltd Buys 247,000 Shares of Roivant Sciences Ltd. $ROIV
Capricorn Fund Managers Ltd significantly increased its holdings in Roivant Sciences Ltd. by 124.4% in Q4, acquiring an additional 247,000 shares to reach a total of 445,500 shares valued at $9.67 million. This strategic move makes Roivant Sciences its 11th largest position, accounting for 2.3% of its portfolio. The article also notes increasing bullish sentiment from analysts, with a "Moderate Buy" consensus and an average target price of $29.50, despite recent insider selling activity.
Roivant Sciences Ltd. (ROIV) Discusses Brepocitinib Program Expansion and Phase III Batoclimab Data Update - Slideshow (NASDAQ:ROIV)
Roivant Sciences Ltd. discusses the expansion of its brepocitinib program and provides an update on Phase III batoclimab data. The information was presented in a slide deck published by the company. This article was written by SA Transcripts, Seeking Alpha's team responsible for transcript-related projects.
Roivant Sciences (ROIV) Is Up 6.8% After Mixed Autoimmune Trial Updates - Has The Bull Case Changed?
Roivant Sciences (ROIV) experienced a 6.8% stock increase following mixed clinical updates in early April 2026. While Immunovant's batoclimab thyroid eye disease studies missed their primary endpoint, Priovant launched a new Phase 2b/3 brepocitinib trial for lichen planopilaris, expanding Roivant's late-stage pipeline in autoimmune conditions. The core investment narrative remains focused on the PDUFA for brepocitinib in dermatomyositis, with attention now also on whether brepocitinib can become a multi-indication franchise despite acknowledging ongoing trial risks.
TD Cowen reiterates Roivant Sciences stock rating on drug launch timing
TD Cowen has reiterated a Buy rating and a $38.00 price target for Roivant Sciences (NASDAQ:ROIV) given the upcoming launch of its drug brepo in September 2026 and a significant $2.3 billion settlement with Moderna. This settlement, including a $950 million upfront payment, strengthens Roivant's financial position, which already holds more cash than debt. This positive outlook is further supported by expected Phase 3 and Phase 2b data in mid-2026 and recent price target increases from other firms following the Moderna settlement.
Roivant (NASDAQ: ROIV) executive settles RSU taxes with shares
Roivant Sciences President and Vant Chair Frank Torti had 160,035 common shares withheld on March 31, 2026, to cover tax obligations from previously granted Restricted Stock Units (RSUs). This "net settlement" transaction, valued at $27.70 per share, means the company withheld shares instead of requiring cash for taxes. Following this, Torti now directly holds 13,576,512 common shares of Roivant.
Roivant Shrugs Off Batoclimab Phase III Failure in TED
Roivant Sciences is reportedly unconcerned about the failure of its Batoclimab Phase III trial for Thyroid Eye Disease (TED). This follows a previous announcement where a trial of Batoclimab was positive, but no filing was planned. The company's recent focus has been on tightening leadership control over Immunovant and narrowing the focus of IMVT-1402.
Roivant Sciences Adds Brepocitinib LPP Trial as Batoclimab Misses Phase III TED Endpoint
Roivant Sciences is expanding the development of its drug brepocitinib into lichen planopilaris (LPP) with a new combined Phase IIb/III trial, targeting an unmet medical need for a severe inflammatory scalp disorder. This move comes as their other drug, batoclimab, failed to meet its primary endpoint in a Phase III trial for thyroid eye disease (TED), leading the company to discontinue TED development for that molecule and shift focus to IMVT-1402 and ongoing Graves' disease studies. The expansion of brepocitinib is supported by strong biological rationale and prior clinical signals in similar Th1-driven skin diseases.
Roivant Advances Brepocitinib Program, Refocuses Autoimmune Portfolio
Roivant Sciences (ROIV) is expanding its brepocitinib program with a new Phase 2b/3 trial for lichen planopilaris, reinforcing its focus on rare rheumatology and dermatology. Concurrently, its subsidiary Immunovant faced setbacks as batoclimab failed to meet primary endpoints in thyroid eye disease trials, leading to a strategic shift towards developing IMVT-1402, an next-generation FcRn blocker, particularly for Graves' disease. Despite financial challenges and a "Hold" rating from one analyst, Roivant exhibits strong pipeline momentum and positive corporate events.
Roivant (Nasdaq: ROIV) shows $4.3B cash and mixed late-stage trial results
Roivant Sciences (Nasdaq: ROIV) reported approximately $4.3 billion in cash and marketable securities as of March 31, 2026, and repurchased nearly 4 million shares for $109.7 million. The company announced a new Phase 2b/3 trial for brepocitinib in lichen planopilaris and received FDA Priority Review for brepocitinib in dermatomyositis, with a PDUFA date in Q3 2026. However, two Phase 3 studies for batoclimab in thyroid eye disease failed to meet their primary endpoint.
Roivant Sciences (ROIV) executive settles CVARs and RSUs into shares
Mayukh Sukhatme, President & CIO of Roivant Sciences (ROIV), recently settled equity awards. He converted over 1.3 million Capped Value Appreciation Rights (CVARs) into 58,391 common shares and had a total of 217,321 common shares withheld for tax obligations related to both CVARs and previously granted Restricted Stock Units (RSUs). Following these transactions, Sukhatme directly holds 18,677,617 Roivant Sciences Common Shares.
(ROIV) as a Liquidity Pulse for Institutional Tactics
This article provides an AI-generated analysis of Roivant Sciences Ltd. (NASDAQ: ROIV) for institutional trading, highlighting a mid-channel oscillation pattern and a favorable risk-reward setup. It outlines three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels, along with multi-timeframe signal analysis. The analysis suggests choppy conditions due to divergent sentiment across various time horizons.
250,468 Shares in Roivant Sciences Ltd. $ROIV Acquired by Exchange Traded Concepts LLC
Exchange Traded Concepts LLC has acquired 250,468 shares of Roivant Sciences (NASDAQ:ROIV), valued at approximately $5.44 million, during the fourth quarter, increasing institutional ownership to 64.76%. Despite recent insider selling by CEO Eric Venker and Frank Torti, analysts maintain a largely positive outlook with a "Moderate Buy" consensus and an average target price of $29.50. The biopharmaceutical company focuses on developing innovative therapies through its "Vants" subsidiary model.
Roivant Sciences Insider Sold Shares Worth $1,921,500, According to a Recent SEC Filing
An insider at Roivant Sciences sold shares valued at $1,921,500, as disclosed in a recent SEC filing. This transaction follows other recent insider sales reported in March, including sales of $5,648,000 and $1,200,573 worth of shares. Roivant Sciences is a biopharmaceutical company focused on developing and commercializing medicines across various therapeutic areas.
Roivant Sciences Ltd (ROIV) Stock Price Quote Today & Current Price Chart
This article provides the current stock price quote and chart for Roivant Sciences Ltd (ROIV). It also mentions that the content is provided by Capital.com, an online trading platform.
Roivant Sciences (NASDAQ: ROIV) director exercises 70K options, sells 70K shares
Meghan Fitzgerald, a director at Roivant Sciences (NASDAQ: ROIV), exercised stock options for 70,000 common shares at $8.80 per share and subsequently sold all 70,000 shares in an open-market transaction at a weighted average price of $27.45 per share. These actions represent a routine liquidity event to convert equity awards into cash. Following the transactions, Fitzgerald directly holds 42,963 common shares, and the exercised option award is now fully vested and exhausted.
Assessing Roivant Sciences (ROIV) Valuation After Brepocitinib Priority Review And Phase 3 VALOR Success
Roivant Sciences' brepocitinib has gained investor attention due to positive Phase 3 VALOR trial results and FDA Priority Review, leading to significant shareholder returns. Despite trading below analyst targets, the company's valuation faces scrutiny, with a popular narrative suggesting undervaluation at $33.25 per share based on potential $10 billion+ peak sales. However, a tougher picture emerges when considering valuation multiples, pointing to possible market over-optimism.
Roivant Sciences Ltd. Experiences Revision in Stock Evaluation Amid Strong Market Performance
Roivant Sciences Ltd. has undergone a stock evaluation revision, with its price currently at $26.52. The company has shown strong performance over the past year and three years, significantly outperforming the S&P 500, despite mixed technical indicators such as bullish MACD and Bollinger Bands but bearish RSI.
ROIV Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Roivant Sciences Ltd (ROIV). It indicates a 'Neutral' overall technical sentiment based on a combination of moving averages and oscillators. Key metrics like RSI, MACD, support/resistance levels, and various moving averages are presented to assess the stock's current standing and potential future movements.
Assessing Roivant Sciences (ROIV) Valuation After Brepocitinib Priority Review And Phase 3 VALOR Success
Roivant Sciences (ROIV) valuation is being reassessed following positive Phase 3 VALOR trial results for brepocitinib and an FDA Priority Review. While the market considers Roivant 20.2% undervalued with a fair value of $33.25, suggesting a potential $10 billion+ peak sales portfolio, investor caution is advised due to execution risks in late-stage trials and ongoing litigation. Despite strong past shareholder returns, a premium P/B ratio compared to industry averages implies much future success is already priced in.
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
The New England Journal of Medicine has published positive Phase 3 VALOR trial results for brepocitinib in dermatomyositis, demonstrating its superiority over placebo in various measures including global disease activity, muscle strength, and skin disease. Brepocitinib 30 mg showed statistically significant and clinically meaningful improvements, enabling reduction in corticosteroid use. The U.S. FDA has granted Priority Review for brepocitinib's New Drug Application with a PDUFA target action date in Q3 2026.
NEJM study: rare muscle-skin disease drug beat placebo in Phase 3
Priovant Therapeutics announced the publication of positive Phase 3 VALOR trial results for brepocitinib 30 mg in dermatomyositis in the New England Journal of Medicine. The drug met its primary endpoint, showing a 15.3-point improvement in Total Improvement Score versus placebo at Week 52, and demonstrated benefits across nine secondary endpoints including significant corticosteroid reduction. The FDA has granted Priority Review for brepocitinib with a PDUFA target action date in Q3 2026, despite observations of increased serious infections in the brepocitinib group, which mostly resolved.
Should Roivant’s Moderna Settlement Shift Investor Focus to Pipeline Execution Risks for Roivant Sciences (ROIV)?
Roivant Sciences recently settled a dispute with Moderna regarding lipid nanoparticle technology, which has shifted investor focus from legal risks to the company's clinical trial milestones. Analysts believe this settlement clears a significant overhang, making the execution of Roivant's pipeline in pulmonary hypertension and non-infectious uveitis the primary short-term catalyst and risk. The company's future profitability hinges on successful trial readouts, with topline data for the PHocus trial expected in the second half of 2026.
Vanguard realignment leads to separate reports for Roivant (ROIV)
The Vanguard Group has filed an amended Schedule 13G/A report for Roivant Sciences Ltd. (ROIV), declaring 0 shares and 0% beneficial ownership following an internal realignment effective January 12, 2026. This realignment means certain Vanguard subsidiaries will now report their holdings separately, as permitted by SEC guidance. The filing clarifies that this update reflects a change in reporting structure rather than an acquisition or disposition of Roivant shares.
Bernstein Initiates Coverage of Roivant Sciences Ltd. (ROIV) with an Outperform Rating
Bernstein has initiated coverage of Roivant Sciences Ltd. (ROIV) with an Outperform rating and a $35 price target, driven by potential upside from upcoming clinical trial readouts for pulmonary hypertension and non-infectious uveitis. This follows recent price target increases by JPMorgan and H.C. Wainwright, both citing positive developments like a settlement with Moderna and litigation proceeds related to lipid nanoparticle technology. The article also includes a promotional section for an AI stock report, asserting that some AI stocks offer greater potential returns than ROIV.
Roivant Sciences (ROIV) CFO reports RSU tax-withholding of 1,546 shares
Roivant Sciences Ltd.'s CFO, Richard Pulik, reported a tax-related disposition of 1,546 Common Shares on March 20, 2026. This "net settlement" was to satisfy tax withholding obligations related to restricted stock unit (RSU) vesting, rather than an open-market sale. Following this transaction, Pulik directly holds 236,867 Common Shares, with the filing indicating it as a routine administrative step for equity-based compensation.
Assenagon Asset Management S.A. Purchases 6,877,348 Shares of Roivant Sciences Ltd. $ROIV
Assenagon Asset Management S.A. significantly increased its stake in Roivant Sciences Ltd. by purchasing an additional 6,877,348 shares in the fourth quarter, bringing their total holdings to 6,937,112 shares valued at approximately $150.5 million. This move highlights institutional confidence, despite recent insider selling totaling over $159 million. The company maintains a "Moderate Buy" consensus rating from analysts, with an average price target of $29.50.
Bernstein initiates Roivant Sciences stock with outperform rating
Bernstein SocGen Group initiated coverage on Roivant Sciences Ltd. (NASDAQ:ROIV) with an outperform rating and a $35.00 price target, suggesting a 26% upside. The firm notes potential upside from upcoming data readouts and considers key risks like Vyvgart's Phase 3 trial results and brepocitinib's launch as already factored into the valuation. This follows significant recent developments, including a $2.25 billion settlement with Moderna and progress in its clinical pipeline.
ROIV: Moderna Settlement Cash Sets Up 2026 Clinical Readout Repricing
Roivant Sciences' (ROIV) fair value has been adjusted upward to $33.25 by analysts, primarily due to the Moderna litigation settlement which provides $2.25 billion in proceeds and removes a significant legal overhang. While bullish views highlight improved financial clarity and focus on clinical readouts, cautious analysts emphasize execution risk with upcoming 2026 clinical data and the contingent nature of some settlement funds. Pulmovant, a Roivant company, has completed Phase 2 enrollment for mosliciguat, with topline data expected in H2 2026.
Roivant Sciences (ROIV) soars 19.4% as pipeline drugs progress
Roivant Sciences (ROIV) shares jumped 19.4% due to significant progress in its drug pipeline. The company is advancing several new drug candidates, which has positively impacted investor confidence and stock performance. This surge indicates market optimism regarding the future potential of their pharmaceutical developments.
Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Rating of "Moderate Buy" from Brokerages
Roivant Sciences Ltd. (NASDAQ:ROIV) has received a consensus "Moderate Buy" rating from eleven brokerages, with an average 12-month target price of $29.50. Despite this, company insiders have sold a significant number of shares recently, totaling over $173 million in the last 90 days. The stock opened at $27.70, with a market cap of approximately $19.82 billion.
(ROIV) Risk Channels and Responsive Allocation
The article provides a detailed analysis of Roivant Sciences Ltd. (NASDAQ: ROIV), highlighting weak near-term sentiment but strong long-term prospects. It outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for various risk profiles, along with multi-timeframe signal analysis and specific entry, target, and stop-loss levels. The report emphasizes the exceptional 37.3:1 risk-reward short setup.
Bernstein initiates Roivant Sciences stock with outperform rating
Bernstein SocGen Group initiated coverage on Roivant Sciences Ltd. (NASDAQ:ROIV) with an outperform rating and a $35.00 price target, predicting a 26% upside. The firm highlights potential gains from upcoming data readouts and considers key risks, such as Vyvgart’s trial results and brepocitinib's launch, to be already factored into the stock's valuation. This initiation follows a significant 153% gain for Roivant Sciences over the past year and recent positive developments, including a $2.25 billion settlement with Moderna and advancements in its clinical pipeline.
Roivant (NASDAQ: ROIV) president exercises 200K options and sells 200K shares
Roivant Sciences Ltd. President & Immunovant CEO Eric Venker recently exercised stock options for 200,000 common shares at $3.85 per share and subsequently sold all 200,000 shares in open-market transactions for a weighted average price of $28.24 per share. Following these transactions, Venker directly owns 1,647,546 common shares. The sale prices ranged from $28.04 to $28.45 according to the SEC filing.
Roivant Sciences Insider Sold Shares Worth $5,648,000, According to a Recent SEC Filing
An insider at Roivant Sciences Ltd. has sold shares valued at $5,648,000, as reported in a recent SEC filing. The biopharmaceutical company is actively developing medicines across various therapeutic areas such as immunology, oncology, hematology, and dermatology. This transaction is one of several insider share sales reported for the company in recent months.
Roivant Sciences (NASDAQ:ROIV) CEO Sells 200,000 Shares
Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker recently sold 200,000 shares of the company's stock, reducing his stake by 10.83%. This sale is part of a series of transactions dating back to December, totaling approximately 875,000 shares sold for about $21.5 million. Despite the insider selling, Wall Street analysts maintain a generally positive outlook on ROIV with an average target price of $28.81.
Roivant Sciences Director Makes Major Insider Move With Eye-Catching Stock Sale
Roivant Sciences director Melissa B. Epperly sold 41,861 shares of company stock for over $1.2 million, highlighting significant insider activity. This sale follows recent positive developments for Roivant, including a $2.25 billion patent settlement and FDA Priority Review for brepocitinib, which have strengthened the company's financial and IP position. Despite a strong pipeline and positive corporate events, Spark, TipRanks’ AI Analyst, rates ROIV as "Neutral" due to persistent losses and cash burn.
Insider Sell Alert: Melissa Epperly Sells 41,861 Shares of Roivant Sciences Ltd (ROIV)
Melissa Epperly, a Director at Roivant Sciences Ltd (ROIV), sold 41,861 shares of the company on March 16, 2026. This transaction is part of a broader trend of insider selling at Roivant Sciences, with 1 insider buy and 38 insider sells over the past year. The stock is currently trading at $28.68, significantly overvalued compared to its GF Value estimate of $3.95.
Roivant Sciences (ROIV) director sells 41,861 common shares
Roivant Sciences Ltd. director Melissa B. Epperly sold 41,861 common shares on March 16, 2026, at a weighted average price of $28.68 per share. The transaction, an open-market sale, reduced her direct holdings to 15,804 shares. This significant insider sale is considered a strong-signal transaction.
Rockefeller Financial files to sell 200,000 Roivant shares | ROIV SEC Filing - Form 144
Rockefeller Financial LLC has filed a Form 144 notice to sell 200,000 common shares of Roivant Sciences Ltd. (ROIV) resulting from an options exercise with a grant date of April 20, 2022, and a proposed transaction date of March 17, 2026. The filing indicates the proceeds will be transmitted by wire. The document also lists previous sales by Eric Venker, including several large transactions of Roivant shares.
Bamco Inc. NY Acquires 105,000 Shares in Roivant Sciences Ltd.
Bamco Inc. NY, an institutional investor, has acquired 105,000 shares in biopharmaceutical company Roivant Sciences Ltd. (NASDAQ:ROIV) during the third quarter of 2026, valued at approximately $1,589,000. This significant investment suggests Bamco Inc. NY sees potential in Roivant's pipeline and future growth prospects, reflecting ongoing institutional interest in the company.
105,000 Shares in Roivant Sciences Ltd. $ROIV Acquired by Bamco Inc. NY
Bamco Inc. NY recently acquired 105,000 shares of Roivant Sciences Ltd. (NASDAQ:ROIV), valued at approximately $1.59 million, bringing total institutional ownership to 64.76%. Despite significant insider selling totaling $184.8 million over the last 90 days, institutional investors are increasing their stakes. The stock currently holds a "Moderate Buy" consensus rating from analysts, with an average target price of $28.81.
Do You Believe in the Growth Prospects of Roivant Sciences Ltd. (ROIV)?
The provided article content is empty. Therefore, a summary cannot be generated.
Roivant Sciences Ltd. $ROIV Shares Purchased by HighVista Strategies LLC
HighVista Strategies LLC significantly increased its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 61.4% in the third quarter, bringing its total holdings to 98,858 shares valued at $1.496 million. Institutional investors collectively own 64.76% of the stock, with several other funds also adding positions. While analysts maintain a "Moderate Buy" rating with a consensus price target of $28.81, company insiders have been net sellers, disposing of over 8 million shares in the last 90 days.
Roivant Sciences Ltd. $ROIV is Foursixthree Capital LP's 7th Largest Position
Foursixthree Capital LP increased its stake in Roivant Sciences Ltd. (ROIV) by 4.2% in the third quarter, making it their 7th largest holding. Despite significant insider selling totaling over $205 million, analysts maintain a "Moderate Buy" consensus rating with an average target price of $28.81. Roivant Sciences, a biopharmaceutical company, focuses on developing and commercializing therapies through its subsidiary "Vants" across various therapeutic areas.
Roivant Sciences Ltd. $ROIV Shares Sold by Prosight Management LP
Prosight Management LP reduced its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 26.2% in the third quarter, selling 473,039 shares, though ROIV remains its 7th largest holding. The article also highlights recent significant insider selling by a director and the CEO, collectively totaling over 10 million shares worth approximately $251 million in the last 90 days. Despite this, analysts maintain a "Moderate Buy" rating with an average price target of $28.81.
Roivant Sciences Ltd. $ROIV Shares Bought by Integral Health Asset Management LLC
Integral Health Asset Management LLC increased its stake in Roivant Sciences (NASDAQ:ROIV) by 25% in the third quarter, now owning 750,000 shares valued at approximately $11.35 million. While institutional investors collectively own 64.76% of the company and analysts have a "Moderate Buy" rating, insiders have been net sellers, divesting over 10 million shares worth $251.4 million in the last 90 days. Roivant Sciences, a biopharmaceutical company, currently trades around its consensus price target of $28.81.
Roivant Sciences stock hits all-time high at 30.31 USD
Roivant Sciences (ROIV) stock has reached an all-time high of $30.31, boosting its market capitalization to $21.66 billion and reflecting a 185.38% increase over the past year. This surge follows significant developments including a $2.25 billion settlement with Moderna and Arbutus Biopharma, and progress in its clinical pipeline with a New Drug Application for Brepo accepted for priority review. Despite this growth, InvestingPro data suggests the stock might be overvalued, placing it on a list of potentially overvalued stocks.
Roivant Sciences stock hits all-time high at 30.31 USD
Roivant Sciences (ROIV) stock has reached an all-time high of $30.31, leading to a market capitalization of $21.66 billion and a 185.38% increase over the past year. This surge is attributed to investor confidence in the company's biotech innovations, recent settlements, and promising clinical pipeline developments. Analysts have reacted positively, raising price targets and reiterating "Buy" and "Outperform" ratings, although InvestingPro data suggests the stock might be overvalued.
Dimensional Fund Advisors LP Has $140.84 Million Stake in Roivant Sciences Ltd. $ROIV
Dimensional Fund Advisors LP significantly increased its stake in Roivant Sciences Ltd. by 18%, bringing its total holding to 9,308,710 shares valued at approximately $140.84 million. This accumulation comes despite substantial insider selling activity, with insiders offloading 13.1 million shares worth over $311 million in the last quarter. Analysts maintain a "Moderate Buy" consensus for Roivant Sciences, with an average target price of $28.81.
Neo Ivy Capital Management Has $3.59 Million Stake in Roivant Sciences Ltd. $ROIV
Neo Ivy Capital Management significantly increased its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 229.6% in the third quarter, now holding 237,392 shares valued at $3.59 million. This makes Roivant Sciences its 18th-largest holding. Despite recent insider selling, largely by Mayukh Sukhatme and Vivek Ramaswamy, analysts maintain a "Moderate Buy" consensus rating with an average price target of $28.81.
